Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

SinuShunt – New disruptive medical device for treatment of hydrocephalus

Description du projet

Une dérivation innovante pour le traitement de l’hydrocéphalie

L’hydrocéphalie est une affection grave associée à l’accumulation de liquide céphalorachidien (LCR) dans le cerveau. Le traitement consiste en l’implantation d’un dispositif de dérivation pour drainer le LCR dans la poitrine ou l’abdomen. Le projet SINUSHUNT, financé par l’UE, a pour but de développer un nouveau dispositif médical implantable drainant le LCR dans la veine sinusale, un lieu de résorption naturelle du LCR. L’utilisation d’une technologie innovante de stent permet de surmonter les problèmes d’obstruction associés aux sorties conventionnelles et d’accroître la durée de vie du dispositif de dérivation, réduisant ainsi le besoin de réopérer et l’apparition d’autres complications.

Objectif

Hydrocephalus is a devastating neurological condition caused by accumulation of cerebrospinal fluid (CSF) on brain, and If left untreated, it can be fatal. The only treatment option is surgical, either implantation of a shunting device placed centrally in the brain, or, in some cases, by use of an endoscope going through the brain substance to its central part. The main problem in the industry is that conventional treatment systems (shunts) are based on a technology from 1950s and they are failing on average in 4-8 years, due to blockage or over-drainage. This results in 100 000 re-operations annually and brings a lot of complications (incl. increased infections) to the patient. Furthermore, this inefficiency represents an additional cost of €1.5B for the health care systems annually. To offer a solution to these problems, CSF-Dynamics is developing a new disruptive implantable medical device for treatment of hydrocephalus. The main innovation is draining the cerebrospinal fluid into sinus vein that is a natural resorption place of CSF, instead of conventional chest or abdomen. The hunt system uses novel stent technology as an outlet into the sinus vein, to avoid obstruction. SinuShunt competitive advantages are: 1) significantly increased life-time of the shunt, therefore reducing amount of re-operations; 2) Better quality of life for the patient due to the close to normal drainage of the brain-fluid, avoiding over-drainage and complications thereof. Hydrocephalus market is currently valued at €1.2B and is expected to reach a value of €1.6B by 2023. The market is steadily growing at CAGR of 4.4% during this time period. The market growth is propelled by growth in aging of population, increasing awareness of the condition and constantly improving diagnostic tools. Our end-users are hydrocephalus patients and users neurosurgeons. By 2026 we expect to sell our solution internationally, employ additional 112 people, and achieve a ROI of 40.6.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

SME-2 - SME instrument phase 2

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) H2020-EIC-SMEInst-2018-2020

Voir tous les projets financés au titre de cet appel

Coordinateur

CSF-DYNAMICS A/S
Contribution nette de l'UE
€ 698 862,50
Adresse
GAMMEL LUNDTOFTEVEJ 1 D
2800 Kgs. Lyngby
Danemark
PME
Oui
Région
Danmark Hovedstaden Københavns omegn
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 998 375,00